Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash & Equivalents (2018 - 2025)

Neurogene (NGNE) has disclosed Cash & Equivalents for 5 consecutive years, with $71.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 6.56% year-over-year to $71.0 million, compared with a TTM value of $71.0 million through Sep 2025, up 6.56%, and an annual FY2024 reading of $136.6 million, changed N/A over the prior year.
  • Cash & Equivalents was $71.0 million for Q3 2025 at Neurogene, up from $58.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $150.1 million in Q1 2024 and bottomed at $58.8 million in Q2 2025.